RxDoctor Payments Data

Katherine Bloom, MD

Allergy & Immunology · Fairfield, CTNPI 1760697635

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $937 and has fallen 50.0% since, to $468 in 2025.

$3,719in general payments, 2019–2025

Across 180 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$721
  • AstraZeneca$572
  • Pfizer$346
  • CSL Behring$332
  • Sanofi$266
  • Takeda Pharmaceuticals U.S.A., Inc.$242
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,68599%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,719 in reported general payments places this provider in the 70th percentile of 54 allergy & immunology providers in Connecticut.

See all allergy & immunology providers in Connecticut

Medicare billing

Part B allowed, 2024
$37,967
Medicare patients
83
Services billed
2,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CutaquigImmun Glob G(Igg)-Hipp/Maltose36$135,747
BivigamImmun Glob G(Igg)/Gly/Iga Ov5012$68,834
XolairOmalizumab17$45,833
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,095
SymbicortBudesonide/Formoterol Fumarate15$3,378
Epinephrine11$1,489
Wixela InhubFluticasone Propion/Salmeterol14$1,083
Azelastine Hcl34$949
Levalbuterol Tartrate HfaLevalbuterol Tartrate12$584
Albuterol Sulfate HfaAlbuterol Sulfate22$451
Montelukast Sodium24$234
Fluticasone Propionate16$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Octapharma USA, Inc.Cutaquig$32$135,74736 claims
GSKTrelegy Ellipta$721$13,09515 claims
AstraZenecaSymbicort$572$3,37815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 54 allergy & immunology providers in Connecticut.

Other allergy & immunology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →